FIGURE 1.

Study design (a) and patient disposition (b). ^†Patients were treated with a disease‐modifying therapy (DMT) for at least 6 months and with suboptimal efficacy within the last 12 months whilst on the DMT. ^‡One patient discontinued before receiving treatment. ^§Of patients who completed the study treatment period, 154 discontinued for “other reasons” before safety follow‐up (of whom 152 took commercial ocrelizumab); 438 rolled over into the long‐term extension study (one additional patient also rolled over); 40 withdrew consent and did not enter safety follow‐up (of whom 25 took commercial ocrelizumab); eight patients entered safety follow‐up; and one patient discontinued before safety follow‐up by “physician decision” (this patient also took commercial ocrelizumab). Note: The per‐protocol (PP) population consisted of 560 patients. Reasons for exclusion from the PP population were: full course of ocrelizumab treatment not completed (n = 37); major protocol deviation deemed to potentially affect the efficacy endpoints (n = 56); and magnetic resonance imaging (MRI) performed after ocrelizumab infusion (n = 80). EDSS, Expanded Disability Status Scale; ITT, intention‐to‐treat; IV, intravenous; NEDA, no evidence of disease activity; OCR, ocrelizumab; RRMS, relapsing‐remitting multiple sclerosis